Latest stories on INBX
Inhibrx, Eikon rise after insider buying
Seeking Alpha63 · neutralgeneral
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Seeking Alpha63 · neutralproduct/pr
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
TipRanks73 · bullishproduct/pr
Inhibrx Biosciences, Inc. (INBX) files 8-K
SEC 8-K50 · neutralgeneral
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Seeking Alpha73 · bullishproduct/pr
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
InvestorsHub67 · bullishproduct/pr
Inhibrx stock jumps on positive cancer drug trial results
Investing.com Markets73 · bullishproduct/pr
Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study
The Fly73 · bullishproduct/pr
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
PR Newswire76 · bullishproduct/pr
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
StockTitan59 · neutralproduct/pr
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
PR Newswire59 · neutralproduct/pr
Citizens reiterates Market Perform on Inhibrx Biosciences stock
Investing.com Analyst Ratings50 · neutralanalyst
INBX, Inhibrx Biosciences | IBD Stock Checkup
Investors.com50 · neutralgeneral
Inhibrx initiated with a Buy at H.C. Wainwright
The Fly61 · neutralanalyst
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target
Investing.com Analyst Ratings61 · neutralanalyst
Inhibrx reports Q2 EPS ($2.34), consensus ($1.85)
The Fly28 · bearishearnings
Inhibrx Biosciences GAAP EPS of -$2.34 beats by $0.05
Seeking Alpha56 · neutralearnings
Inhibrx Biosciences, Inc. (INBX) files 8-K
SEC 8-K50 · neutralgeneral
Inhibrx Reports Second Quarter 2026 Financial Results
PR Newswire50 · neutralgeneral
Inhibrx Biosciences: The Whole Story Rides On INBRX-106
Seeking Alpha48 · neutralgeneral
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Seeking Alpha67 · bullishproduct/pr
Inhibrx Biosciences Expands Credit Facility to $500 Million
TipRanks55 · neutralgeneral
Inhibrx Biosciences, Inc. (INBX) files 8-K
SEC 8-K50 · neutralgeneral
Inhibrx Shares Fall After Expanding Loan Agreement to $500 Million
Morningstar34 · bearishgeneral